Through the looking glass: The protein science of biosimilars

Clinical and Experimental Nephrology

Volumn 11, Issue 3, 2007, Pages 191-195

  Goldsmith, David ^a   Kuhlmann, Martin ^b   Covic, Adrian ^c  

^a GUY S HOSPITAL   (United Kingdom)

^b VIVANTES KLINIKUM IM FRIEDRICHSHAIN   (Germany)

^c C I PARHON NATIONAL INSTITUTE OF ENDOCRINOLOGY   (Romania)

Author keywords

Assays; Biopharmaceuticals; Biosimilars; Glycosylation; Manufacturing; Pharmacovigilance

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; BASILIXIMAB; BECAPLERMIN; BETA1A INTERFERON; BEVACIZUMAB; BIOLOGICAL PRODUCT; BLOOD CLOTTING FACTOR 8; CONSENSUS INTERFERON; DACLIZUMAB; DORNASE ALFA; ETANERCEPT; FLUOXETINE; HUMAN GROWTH HORMONE; IMIGLUCERASE; INDINAVIR; INSULIN ASPART; INSULIN LISPRO; MAB THERA; METFORMIN; OKT 3; PACLITAXEL; PAROXETINE; RANITIDINE; RECOMBINANT ALPHA2A INTERFERON; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; RITUXIMAB; ROFECOXIB; SIMVASTATIN; TOSITUMOMAB I 131; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANEMIA; BIOTECHNOLOGY; CHO CELL; CHRONIC KIDNEY DISEASE; COMPARATIVE STUDY; DRUG CLEARANCE; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; DRUG MANUFACTURE; DRUG MARKETING; DRUG PURIFICATION; DRUG SAFETY; DRUG STRUCTURE; DRUG SURVEILLANCE PROGRAM; ESCHERICHIA COLI; EXPRESSION VECTOR; FERMENTATION; GENE DELIVERY SYSTEM; GENE EXPRESSION SYSTEM; HUMAN; HYBRIDOMA; IMMUNOGENICITY; ISOELECTRIC FOCUSING; MOLECULAR WEIGHT; NONHUMAN; PATENT; PROCESSING; PROTEIN GLYCOSYLATION; PROTEIN PROCESSING; REVIEW; SCALE UP; SIALYLATION; STRUCTURE ACTIVITY RELATION; YEAST;

ANEMIA; ANIMALS; BIOPHARMACEUTICS; DRUG TOXICITY; ERYTHROPOIETIN, RECOMBINANT; KIDNEY FAILURE, CHRONIC; MOLECULAR STRUCTURE; PROTEIN ENGINEERING; PROTEIN PROCESSING, POST-TRANSLATIONAL;

EID: 34748907902     PISSN: 13421751     EISSN: 14377799     Source Type: Journal    
DOI: 10.1007/s10157-007-0487-2     Document Type: Review

References (40)

1. Committee for Medicinal Products for Human Use. Guidelines on similar biological medicinal products containing biotechnology-derived proteins as active substance: quality issues. European Medicines Agency EMEA/CHMP/BWP/49348/ 2005 2005
2. EuropaBio. The biotech industry's views on the pharma review package. Available at http://europabio.org/positions/posPharma.ppt Accessed Dec 2006
3. H Schellekens 2004 Biosimilar therapeutic agents: issues with bioequivalence and immunogenicity Eur J Clin Invest 34 797 9
4. G Walsh R Jefferis 2006 Post-translational modifications in the context of therapeutic proteins Nat Biotechnol 24 1241 52
5. TU Gerngross 2004 Advances in the production of human therapeutic proteins in yeasts and filamentous fungi Nat Biotechnol 22 1409 14
6. S Elliott J Egrie J Browne T Lorenzini L Busse N Rogers 2004 Control of rHuEPO biological activity: the role of carbohydrate Exp Hematol 32 1146 55
7. RK Sylvester 2002 Clinical applications of colony-stimulating factors: a historical perspective Am J Health Syst Pharm 59 S6 12
8. TS Raju JB Briggs SM Borge AJ Jones 2000 Species-specific variation in glycosylation of IgG: evidence for the species-specific sialylation and branch-specific galactosylation and importance for engineering recombinant glycoprotein therapeutics Glycobiology 10 477 86
9. T Misaizu S Matsuki TW Strickland M Takeuchi A Kobata S Takasaki 1995 Role of antennary structure of N-linked sugar chains in renal handling of recombinant human erythropoietin Blood 86 4097 104
10. Bendig MM. The production of foreign proteins in mammalian cells. Genet Eng 1988;91-127
11. I Hunt 2005 From gene to protein: a review of new and enabling technologies for multi-parallel protein expression Protein Expr Purif 40 1 22
12. A Dove 2001 Betting on biogenerics Nat Biotechnol 19 117 20
13. KA Thiel 2004 Biomanufacturing, from bust to boom... to bubble? Nat Biotechnol 22 1365 72
14. M Hoglund 1998 Glycosylated and non-glycosylated recombinant human granulocyte colony-stimulating factor (rhG-CSF)-what is the difference? Med Oncol 15 229 33
15. A Hooker D James 1998 The glycosylation heterogeneity of recombinant human IFN-gamma J Interferon Cytokine Res 18 287 95
16. F Meuwly U Weber T Ziegler A Gervais R Mastrangeli C Crisci 2006 Conversion of a CHO cell culture process from perfusion to fed-batch technology without altering product quality J Biotechnol 123 106 16
17. A Dove 2002 Uncorking the biomanufacturing bottleneck Nat Biotechnol 20 777 9
18. L Chu DK Robinson 2001 Industrial choices for protein production by large-scale cell culture Curr Opin Biotechnol 12 180 7
19. G Dutton 2000 Improved tools for large-scale bioprocessing Genet Eng News 20 57 63
20. RN Pattison J Swamy B Mendenhall C Hwang BT Frohlich 2000 Measurement and control of dissolved carbon dioxide in mammalian cell culture processes using an in situ fiber optic chemical sensor Biotechnol Prog 16 769 74
21. T Sugiura HB Maruyama 1992 Factors influencing expression and post-translational modification of recombinant protein C J Biotechnol 22 353 60
22. DW Jayme SR Smith 2000 Media formulation options and manufacturing process controls to safeguard against introduction of animal origin contaminants in animal cell culture Cytotechnology 33 27 36
23. BS Kendrick JL Cleland X Lam T Nguyen TW Randolph MC Manning 1998 Aggregation of recombinant human interferon gamma: kinetics and structural transitions J Pharm Sci 87 1069 76
24. A Braun L Kwee MA Labow J Alsenz 1997 Protein aggregates seem to play a key role among the parameters influencing the antigenicity of interferon alpha (IFN-alpha) in normal and transgenic mice Pharm Res 14 1472 8
25. ME Cromwell E Hilario F Jacobson 2006 Protein aggregation and bioprocessing AAPS J 8 E572 9
26. E Balaguer U Demelbauer M Pelzing V Sanz-Nebot J Barbosa C Neususs 2006 Glycoform characterization of erythropoietin combining glycan and intact protein analysis by capillary electrophoresis - electrospray - time-of-flight mass spectrometry Electrophoresis 27 2638 50
27. MJ Gramer CF Goochee 1993 Glycosidase activities in Chinese hamster ovary cell lysate and cell culture supernatant Biotechnol Prog 9 366 73
28. K Ahrer A Jungbauer 2006 Chromatographic and electrophoretic characterization of protein variants J Chromatogr B Analyt Technol Biomed Life Sci 841 110 22
29. B DiPaolo A Pennetti L Nugent K Venkat 1999 Monitoring impurities in biopharmaceuticals produced by recombinant technology Pharm Sci Technol Today 2 70 82
30. PL Storring RJ Tiplady RE Gaines Das B Rafferty YG Mistry 1996 Lectin-binding assays for the isoforms of human erythropoietin: comparison of urinary and four recombinant erythropoietins J Endocrinol 150 401 12
31. CT Yuen PL Storring RJ Tiplady M Izquierdo R Wait CK Gee 2003 Relationships between the N-glycan structures and biological activities of recombinant human erythropoietins produced using different culture conditions and purification procedures Br J Haematol 121 511 26
32. H Schellekens 2005 Follow-on biologics: challenges of the "next generation Nephrol Dial Transplant 20 Suppl 4 iv31 6
33. C Combe RL Tredree H Schellekens 2005 Biosimilar epoetins: an analysis based on recently implemented European Medicines Evaluation Agency guidelines on comparability of biopharmaceutical proteins Pharmacotherapy 25 954 62
34. CA Schmidt AS Ramos JEP da Silva M Fronza SL Dalmora 2003 Activity evaluation and characterization of recombinant human erythropoietin in pharmaceutical products Arq Bras Endocrinol Metabol 47 183 9
35. S Louet 2003 Lessons from Eprex for biogeneric firms Nat Biotechnol 21 956 7
36. M Karpusas A Whitty L Runkel P Hochman 1998 The structure of human interferon-beta: implications for activity Cell Mol Life Sci 54 1203 16
37. JG Gribben S Devereux NS Thomas M Keim HM Jones AH Goldstone 1990 Development of antibodies to unprotected glycosylation sites on recombinant human GM-CSF Lancet 335 434 7
38. H Schellekens 2002 Bioequivalence and the immunogenicity of biopharmaceuticals Nat Rev Drug Discov 1 457 62
39. H Schellekens 2004 How similar do "biosimilars" need to be? Nat Biotechnol 22 1357 9
40. H Schellekens JC Ryff 2002 "Biogenerics": the off-patent biotech products Trends Pharmacol Sci 23 119 21